Upregulation of miR-361-3p Is Associated With Impaired AT2 Receptor Expression in Cardiometabolic Diseases

Abstract

Cardiometabolic homeostasis has been shown to be regulated by the brain Renin-Angiotensin System (RAS), including via epigenetic mechanisms. MicroRNA (miRNA) regulation is one of the most common mechanisms controlling the expression of RAS genes and has previously been implicated in hypertension, cardiac ischemia, and aging. Recently, we observed that hypercaloric diet (HCD) programming resulted in differentially expressed miRNA in the hypothalamus of only the male progeny, including miR-361-3p which is thought to target angiotensin-II type 2 receptors (AT2R). Here, we aimed to investigate whether miR-361-3p regulate AT2R expression in a mouse model of cardiometabolic disease (CMD) exhibiting hypertension, diabetes and obesity. C57BI/6J mice (3-week-old, both sexes, n=10) were fed a HCD (D12492. 60 kcal% Fat, Research Diets, USA) while weight and fasting blood glucose levels were measured weekly to ensure the acquisition of metabolic syndrome. At 12 weeks of age, the mice were infused subcutaneously (osmotic pump model 1004, Alzet) with Ang-II (600 ng/kg/min/4 weeks). BP, food intake and glycemia were recorded weekly while intraperitoneal glucose (GTT), insulin (ITT) tolerance tests and body composition (EchoMRI) were assessed at the end of the study. Gene expression of miR-361-3p (QRT-PCR) was increased in the hypothalamus of CMD male mice (2.0 ±0.5 vs.1.2 ±0.2, p<0.05) but not in females (2.7 ±0.8 vs.2.5 ±0.4, P>0.05). However, both sexes showed an increase in the heart (Males: 2.0 ±0.5 vs.1.0 ±0.3; Females: 1.6 ±0.4 vs. 0.8 ±0.2, p<0.05) which was associated with decreased AT2R cardiac expression (Capillary Western) in CMD male (0.9 ±0.0 vs.1.0 ±0.0, p<0.05) and females (0.1 ±0.0 vs.0.6 ±0.1, p<0.001). Together, our data suggest that in CMD, upregulation of miR-361-3p is associated with the decrease of AT2R in the heart, possibly contributing to impaired cardiac function in this model. This positions inhibitors of miR-361-3p as a possible new therapeutic strategy to control RAS overactivity in CMD. This work was supported in part by a research grant from the National Institutes of Health (HL163588). This is the full abstract presented at the American Physiology Summit 2024 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.